A Study on the Treatment of Parkinson's Disease With Autologous Neural Stem Cells

General Information

Summary This is a single center, single arm and open-label study to investigate the safety and efficacy of iPS-NCS with Parkinson's Disease.
Clinical trials phase Other
Start date (estimated) 2019-02-01
End date (estimated) 2021-02-01
Clinical feature
Label Parkinson's disease
Link http://purl.obolibrary.org/obo/DOID_14330
Description A synucleinopathy that has_material_basis_in degeneration of the central nervous system that often impairs motor skills, speech, and other functions.; Xref MGI. OMIM mapping confirmed by DO. [SN].

Administrative Information

NCT number NCT03815071
ICTRP weblink https://trialsearch.who.int/Trial2.aspx?TrialID=NCT03815071
Other study identifiers
Source weblink https://clinicaltrials.gov/show/NCT03815071
Public contact
Email allife@allifetech.com
Public email allife@allifetech.com
City Beijing
Sponsors Allife Medical Science and Technology Co., Ltd.


Which differentiated cell type is used
Label neural stem cell
Link http://purl.obolibrary.org/obo/CL_0000047
Description An undifferentiated neural cell that originates from the neuroectoderm and has the capacity both to perpetually self-renew without differentiating and to generate multiple central nervous system neuronal and glial cell types.


Recruitment Status Not yet recruiting
Estimated number of participants 10